StockNews.AI
ONCY
StockNews.AI
186 days

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

1. Oncolytics Biotech (ONCY) received a Nasdaq delinquency notification for low share price. 2. The company's share price has been below $1.00 for 30 consecutive days.

3m saved
Insight
Article

FAQ

Why Bearish?

A notification from Nasdaq often triggers investor concern, potentially leading to sell-offs. Historical instances show similar notifications negatively impacted stock prices significantly.

How important is it?

Non-compliance with Nasdaq listing requirements is critical for stock stability and investor confidence. Such notifications affect perceptions and can influence broader market reactions.

Why Short Term?

The immediate concern over compliance might lead to short-term price declines. Past cases of similar notifications have resulted in rapid market reactions.

Related Companies

NASDAQ: ONCY
SAN DIEGO and CALGARY, AB , Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on February 13, 2025 indicating that the Company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company's ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

Related News